Pharma company Ranbaxy Laboratories today said it has received the final approval of the Canadian drug regulator Therapeutic Products Directorate (TPD) to market and manufacture 'Ran-Amlodipine tablets', used in treating hypertensions.
The company has got the approval for Ran-Amlodipine (Amlodipine Besylate tablets) in 5 and 10 mg strengths, through its wholly-owned subsidiary Ranbaxy Pharmaceuticals- Canada Inc (RPCI), Gurgaon-based (RPCI) said in a statement.
"We look forward to marketing both strengths of Ran-Amlodipine tablets at affordable prices that will be beneficial to both the Canadian healthcare system, and most importantly to Canadian patients," RPCI President Paul Drake said.
The total market for Amlodipine Besylate tablets in Canada is 456 million Canadian dollars.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app